Newer approaches to gemcitabine-based therapy of pancreatic cancer: Fixed-dose-rate infusion and novel agents

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 4 SUPPL., 2003, Pages 24-30

  Hochster, Howard S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fixed dose rate; Gemcitabine; Novel agents; Pancreatic cancer

Indexed keywords

CHEMOTHERAPY; CYTOLOGY; TOXICITY; TUMORS;

CYTOTOXICITY;

ONCOLOGY;

DOCETAXEL; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

APOPTOSIS; BLOOD LEVEL; CANCER CHEMOTHERAPY; CELL GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; HUMAN; MULTICENTER STUDY; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STANDARD;

EID: 0038121456     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00447-4     Document Type: Review

References (42)

1. Heinemann V., Xu Y.Z., Chubb S., et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 38:1990;567-572.
2. Huang P., Chubb S., Hertel L.W., et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
3. Heinemann V., Schulz L., Issels R.D., et al. Gemcitabine A modulator of intracellular nucleotide, and deoxynucleotide metabolism . Semin Oncol. 22:(Suppl. 11):1995;11-18.
4. Plunkett W., Huang P., Xu Y.Z., et al. Gemcitabine Metabolism, mechanisms of action, and self-potentiation . Semin Oncol. 22:(Suppl. 11):1995;3-10.
5. Huang P., Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 22:(Suppl. 11):1995;19-25.
6. Grunewald R., Kantarjian H., Du M., et al. Gemcitabine in leukemia A phase I clinical, plasma, and cellular pharmacology study . J Clin Oncol. 10:1992;406-413.
7. Patel S.R., Gandhi V., Jenkins J., et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 19:2001;3483-3489.
8. Brand R., Capadano M., Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 15:1997;331-341.
9. Tempero M., Plunkett W., Ruiz van Haperen V., et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate infusion in metastatic pancreatic adenocarcinoma. [Abstract] Proc Am Soc Clin Oncol. 18:1999;273a.
10. Ruiz van Haperen V.W.T., Du M., Ayres M., et al. Accumulation of gemcitabine triphosphate in cells during high-dose therapy Gemcitabine dose and rate dependence . [Abstract] Proc Am Assoc Cancer Res. 39:1998;187.
11. Rainey J.M., Rinaldi D., Lormand N., et al. A phase I trial of gemcitabine (GEM), administered as a constant dose-rate infusion, and paclitaxel (PAC) in patients with advanced solid tumors (LOA-2A). [Abstract] Proc Am Soc Clin Oncol. 20:2001;92a.
12. Garland L.L., Wagner H J.r, Shaw G.S., et al. Phase I study of constant dose rate infusion gemcitabine with Taxotere in advanced non-small cell lung cancer. [Abstract] Proc Am Soc Clin Oncol. 18:1999;504a.
13. Madajewicz S., Hentschel P., Burns P., et al. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patient with solid tumor malignancies. J Clin Oncol. 18:2000;3553-3557.
14. Louvet C., Andre T., Lledo G., et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma Final results of a GERCOR multicenter phase II study . J Clin Oncol. 20:2002;1512-1518.
15. Cascinu S., Frontini L., Labianca R., et al. A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) . Ann Oncol. 11:2000;1309-1311.
16. Gandhi V., Plunkett W., Du M., et al. Prolonged infusion of gemcitabine Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia . J Clin Oncol. 20:2002;665-673.
17. Rizzieri D.A., Bass A.J., Rosner G.L., et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol. 20:2002;674-679.
18. DiNunno L., Bonomi P., Nabrinski S., et al. Results of a phase II study of gemcitabine (GEM) as second line therapy in advanced non small cell lung cancer (NSCLC). [Abstract] Proc Am Soc Clin Oncol. 19:2000;513a.
19. Kwan P., Mukhopadhyay P., Rastogi A., et al. A novel administration of gemcitabine (G) (via a constant dose rate) in combination with docetaxel (D) in advanced non-small cell lung cancer. [Abstract] Proc Am Soc Clin Oncol. 19:2000;507a.
20. Rigas J.R., Rothenberg M.L., Davis T.H., et al. Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules. [Abstract] Proc Am Soc Clin Oncol. 18:1999;226a.
21. Mani S., Kugler J.W., Knost J.A., et al. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer Minimal activity in colorectal cancer . Invest New Drugs. 16:1999;275-278.
22. Tan B.R., Govindan R., Rader J.S., et al. RFS 2000 (9-NC) with short or constant rate infusion gemcitabine (GEM) in patients (pts) with refractory tumors. [Abstract] Proc Am Soc Clin Oncol. 19:2000;221a.
23. Hensley M.L., Venkatraman E., Maki R., et al. Docetaxel (D) plus gemcitabine (G) is active in leiomyosarcoma (LMS) Results of a phase II trial . [Abstract] Proc Am Soc Clin Oncol. 20:2001;353a.
24. Shord S.S., Faucette S., Hawke R., et al. Interindividual variability in gemcitabine pharmacokinetics Fixed dose rate fails to reliably achieve desired plasma concentrations in patients with non-small cell lung cancer . [Abstract] Proc Am Soc Clin Oncol. 20:2001;92a.
25. Borner M.M., Kralidis E., Friess H. Raltitrexed (Tomudex), and gemcitabine A phase II study in advanced pancreatic cancer . [Abstract] Proc Am Soc Clin Oncol. 21:2002;98b.
26. Scheithauer W., Schüll B., Ulrich-Pur H., et al. Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma. [Abstract] Proc Am Soc Clin Oncol. 21:2002;126a.
27. O'Reilly E.M., Lenzi R., Mani S., et al. Final results of a phase I study of DX-8951f (DX) and gemcitabine (Gem) in advanced solid tumor malignancies. [Abstract] Proc Am Soc Clin Oncol. 21:2002;99a.
28. Vogelzang N.J., Rusthoven J., Paoletti P., et al. Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. [Abstract] Proc Am Soc Clin Oncol. 21:2002;2a.
29. Kindler H.L., Dugan W., Hochster H., et al. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. [Abstract] Proc Am Soc Clin Oncol. 21:2002;125a.
30. Gonzales-Baron M., Mel R., Bolanos M., et al. Phase II study of a fixed-dose rate infusion of gemcitabine associated to UFT in advanced pancreatic cancer. Proc Am Soc Clin Oncol. 21:2002;A601.
31. De Castro J., Bolanos M., Cruz M.A., et al. Phase II trial of gemcitabine plus UFT for the treatment of advanced pancreatic cancer Preliminary results . Proc Am Soc Clin Oncol. 20:2001;A2310.
32. Bramhall S.R., Rosemurgy A., Brown P.D., et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer A randomized trial . J Clin Oncol. 19:2001;3447-3455.
33. Moore M.J., Hamm J., Eisenberg P., et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 19:2000;240a.
34. Van Cutsem E., Karasek P., Oettle H., et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). [Abstract] Proc Am Soc Clin Oncol. 21:2002;130a.
35. Abbruzzese J.L., Rosenberg A., Xiong Q., et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 20:2001;130a.
36. Herbst R.S., Kies M.S. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist. 7:(Suppl. 4):2002;9-15.
37. Gonzalez-Larriba J.L., Giaccone G., van Oosterom A.T., et al. ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours Final results of a phase I trial . [Abstract] Proc Am Soc Clin Oncol. 21:2002;95a.
38. Ratain M.J., George C.M., Janisch L., et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. [Abstract] Proc Am Soc Clin Oncol. 21:2002;76b.
39. Safran H., Ramanathan R., Schwartz J., et al. Herceptin and gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 37:(Suppl. 6):2001;S310.
40. Hecht J., Bedford R., Abbruzzese J., et al. A phase I/II trial of intratumoral endoscopic ultrasound (EUS) injection on Onyx-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Proc Am Soc Clin Oncol. 19:2000;A1039.
41. Xiong HQ, Du M, Wolff RA, et al. Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer [Abstract]. Proc Am Soc Clin Oncol 2002;21:113a.
42. Ryan D.P., Eder J.P., Winkelmann J., et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. [Abstract] Proc Am Soc Clin Oncol. 21:2002;95a.